219 related articles for article (PubMed ID: 34343561)
1. Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents.
Tsoi LC; Patrick MT; Shuai S; Sarkar MK; Chi S; Ruffino B; Billi AC; Xing X; Uppala R; Zang C; Fullmer J; He Z; Maverakis E; Mehta NN; Perez White BE; Getsios S; Helfrich Y; Voorhees JJ; Kahlenberg JM; Weidinger S; Gudjonsson JE
J Allergy Clin Immunol; 2022 Feb; 149(2):640-649.e5. PubMed ID: 34343561
[TBL] [Abstract][Full Text] [Related]
2. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
[TBL] [Abstract][Full Text] [Related]
3. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.
Onsun N; Akaslan TÇ; Sallahoglu K; Gülcan AS; Bulut H; Yabacı A
J Dermatolog Treat; 2022 May; 33(3):1727-1732. PubMed ID: 33704001
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.
Zaba LC; Suárez-Fariñas M; Fuentes-Duculan J; Nograles KE; Guttman-Yassky E; Cardinale I; Lowes MA; Krueger JG
J Allergy Clin Immunol; 2009 Nov; 124(5):1022-10.e1-395. PubMed ID: 19895991
[TBL] [Abstract][Full Text] [Related]
5. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
[TBL] [Abstract][Full Text] [Related]
6. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
[TBL] [Abstract][Full Text] [Related]
7. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis.
He H; Bissonnette R; Wu J; Diaz A; Saint-Cyr Proulx E; Maari C; Jack C; Louis M; Estrada Y; Krueger JG; Zhang N; Pavel AB; Guttman-Yassky E
J Allergy Clin Immunol; 2021 Jan; 147(1):199-212. PubMed ID: 32709423
[TBL] [Abstract][Full Text] [Related]
8. Association of the Psoriatic Microenvironment With Treatment Response.
Wang G; Miao Y; Kim N; Sweren E; Kang S; Hu Z; Garza LA
JAMA Dermatol; 2020 Oct; 156(10):1057-1065. PubMed ID: 32876657
[TBL] [Abstract][Full Text] [Related]
9. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
10. Measurement of circulating miRNA-125a exhibits good value in the management of etanercept-treated psoriatic patients.
Pei D; Cao J; Qin G; Wang X
J Dermatol; 2020 Feb; 47(2):140-146. PubMed ID: 31820498
[TBL] [Abstract][Full Text] [Related]
11. Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling.
Johnston A; Guzman AM; Swindell WR; Wang F; Kang S; Gudjonsson JE
Br J Dermatol; 2014 Jul; 171(1):97-107. PubMed ID: 24601997
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Giuliano A; Sabato S; Stramazzotti D; Gulini E; Dusi D; De Blasio S; Fabris G; Offidani A
Int J Immunopathol Pharmacol; 2009; 22(2):371-7. PubMed ID: 19505391
[TBL] [Abstract][Full Text] [Related]
13. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
Oliver R; Krueger JG; Glatt S; Vajjah P; Mistry C; Page M; Edwards H; Garcet S; Li X; Dizier B; Maroof A; Watling M; El Baghdady A; Baeten D; Ionescu L; Shaw S
Br J Dermatol; 2022 Apr; 186(4):652-663. PubMed ID: 34687214
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF agents for paediatric psoriasis.
Sanclemente G; Murphy R; Contreras J; García H; Bonfill Cosp X
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010017. PubMed ID: 26598969
[TBL] [Abstract][Full Text] [Related]
15. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2.
Johansen C; Funding AT; Otkjaer K; Kragballe K; Jensen UB; Madsen M; Binderup L; Skak-Nielsen T; Fjording MS; Iversen L
J Immunol; 2006 Feb; 176(3):1431-8. PubMed ID: 16424170
[TBL] [Abstract][Full Text] [Related]
16. Regulated genes in psoriatic skin during treatment with fumaric acid esters.
Onderdijk AJ; Balak DM; Baerveldt EM; Florencia EF; Kant M; Laman JD; van IJcken WF; Racz E; de Ridder D; Thio HB; Prens EP
Br J Dermatol; 2014 Oct; 171(4):732-41. PubMed ID: 24852654
[TBL] [Abstract][Full Text] [Related]
17. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
18. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
19. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
